微生物组市场规模、份额和增长分析（按产品、应用和地区）- 产业预测 2025-2032

2023 年全球微生物组市场规模价值9.11 亿美元，预测期内（2025-2032 年）的复合年增长率为17.7%，从2024 年的10.7225 亿美元增长至2032 年的39.4918 亿美元。将成长至1000万美元。

由于创新产品的涌入以及旨在研究和开发微生物组疗法的策略伙伴关係关係的增加，微生物组市场正在经历显着增长。美国国立卫生研究院人类微生物组计划等倡议正在增进我们对微生物组如何影响健康和疾病的理解。值得注意的合作，例如Hudson研究所于 2022 年 1 月与 BiomeBank 达成的四年协议，凸显了我们对发现微生物治疗方法的持续承诺。此外，与微生物组相关的疾病发病率的上升进一步推动了对标靶治疗的需求。随着兴趣和研究的扩大，微生物组领域的新应用和治疗选择的潜力不断增长，为这个不断发展的市场的相关人员提供了充满希望的机会。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究

微生物组市场规模（依产品）

• 市场概况
• 益生菌
• 食物
• 益生元
• 医疗食品
• 其他的

微生物组市场规模（依应用）

• 市场概况
• 治疗
• 诊断

微生物组市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Seres Therapeutics（USA）
• Ferring Pharmaceuticals（Switzerland）
• BiomeBank（Australia）
• Seed Health（USA）
• International Flavors & Fragrances Inc.（USA）
• Pendulum Therapeutics（USA）
• BioHM Health Inc.（USA）
• Actial Farmaceutica SRL（Italy）
• Optibiotix Health plc（UK）
• Resbiotic（USA）
• Infinant Health Inc.（USA）
• Biogaia AB（Sweden）
• Exegi Pharma LLC（USA）
• Vedanta Biosciences Inc.（USA）
• Enterome（France）
• Yakult（Japan）
• DuPont（USA）
• Metabiomics Corporation（USA）
• ViThera Pharmaceuticals（USA）
• Second Genome（USA）

结论和建议

Global Microbiome Market size was valued at USD 911.0 million in 2023 and is poised to grow from USD 1072.25 million in 2024 to USD 3949.18 million by 2032, growing at a CAGR of 17.7% during the forecast period (2025-2032).

The microbiome market is experiencing significant growth due to rising strategic partnerships aimed at research and development of microbiome therapies, alongside an influx of innovative product introductions. Initiatives like the Human Microbiome Project by the NIH are enhancing our understanding of how microbial flora impacts health and disease. Notable collaborations, such as the four-year agreement between Hudson Institute and BiomeBank in January 2022, highlight the ongoing commitment to discovering microbial treatments. Additionally, the escalating incidence of diseases linked to the microbiome is further fueling the demand for targeted therapies. As interest and research expand, the potential for new applications and treatment options in the microbiome space continues to increase, presenting promising opportunities for stakeholders in this evolving market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Microbiome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Microbiome Market Segmental Analysis

Global Microbiome Market is segmented by Product, Application and region. Based on Product, the market is segmented into Probiotics, Foods, Prebiotics, Medical food and Others. Based on Application, the market is segmented into Therapeutics and Diagnostics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Microbiome Market

The Global Microbiome market is driven by a heightened emphasis on the development of therapeutics targeting the human microbiome, particularly within the gut. Research has shown the vital role that gut microbiomes play in enhancing the effectiveness of medicinal drugs, with an optimal balance of microorganisms aiding in the treatment of various diseases. This relationship between specific bacteria and disease states paves the way for innovative medication and vaccine development. Significant investments in microbiome research, such as the National Institutes of Health's $215 million for the Human Microbiome Project and substantial EU funding initiatives like MetaHIT and Horizon 2020, underline this growing interest and increase in popularity for microbiome-based treatments.

Restraints in the Global Microbiome Market

The global microbiome market faces significant restraints primarily due to stringent government regulations. Notably, probiotics have yet to be recognized by the FDA as approved live biotherapeutic products, despite the availability of FDA-regulated foods and dietary supplements that contain these live organisms. These products cannot be marketed as effective treatments for diseases, which limits their potential in the marketplace. While some probiotics are currently undergoing clinical trials for potential future approval as biologics, the uncertainty surrounding FDA regulations poses a challenge for investment and research. Stricter regulatory measures could require extensive R&D efforts, discouraging significant investment and potentially stalling market growth.

Market Trends of the Global Microbiome Market

The Global Microbiome market is witnessing a notable trend of increasing collaborations between public and private organizations, driven by the proliferation of small innovative players. This dynamic landscape presents significant growth opportunities for key stakeholders seeking to acquire companies focused on microbiome research to discover new drugs and targets for various health conditions, including obesity, liver disorders, diabetes, and metabolic issues. As major market leaders prioritize strategic alliances and partnerships, the last two years have seen a surge in collaborative efforts to enhance product development pipelines through robust R&D initiatives, indicating a vibrant and evolving market poised for expansion.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Microbiome Market Size by Product & CAGR (2025-2032)

• Market Overview
• Probiotics
• Foods
• Prebiotics
• Medical food
• Others

Global Microbiome Market Size by Application & CAGR (2025-2032)

• Market Overview
• Therapeutics
• Diagnostics

Global Microbiome Market Size & CAGR (2025-2032)

• North America (Product, Application)
  • US
  • Canada
• Europe (Product, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Seres Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BiomeBank (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seed Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• International Flavors & Fragrances Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pendulum Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioHM Health Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Actial Farmaceutica SRL (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Optibiotix Health plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Resbiotic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Infinant Health Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogaia AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exegi Pharma LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vedanta Biosciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enterome (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Yakult (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DuPont (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabiomics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViThera Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Second Genome (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations